{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:40:28Z","timestamp":1787938828607,"version":"build-2784847793"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00818","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T04:20:32Z","timestamp":1597206032000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose\u2014Possible Predictors of Cardiac Outcomes"],"prefix":"10.3389","volume":"11","author":[{"given":"Volker","family":"Limmroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Lassek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Baier-Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Wendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Dechend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Haverkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J Biol Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1080\/14656566.2017.1373093","article-title":"Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis","volume":"18","author":"Thomas","year":"2017","journal-title":"Expert Opin. Pharmacother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","article-title":"Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications","volume":"168","author":"Camm","year":"2014","journal-title":"Am Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.msard.2014.05.005","article-title":"First-dose effects of fingolimod: pooled safety data from three phase 3 studies","volume":"3","author":"DiMarco","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"B9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00415-013-7115-8","article-title":"Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study","volume":"261","author":"Gold","year":"2014","journal-title":"J Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1177\/0091270006289853","article-title":"FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects","volume":"46","author":"Schmouder","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3389\/fnins.2017.00540","article-title":"Modulation of cardiac autonomic function by fingolimod initiation and predictors for fingolimod induced bradycardia in patients with multiple sclerosis","volume":"11","author":"Li","year":"2017","journal-title":"Front Neurosci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/1352458514538885","article-title":"The autonomic balance predicts cardiac responses after the first dose of fingolimod","volume":"21","author":"Rossi","year":"2015","journal-title":"Mult Scler J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fneur.2020.00391","article-title":"Fingolimod leads to immediate immunological changes within 6 h after first administration","volume":"11","author":"Sehr","year":"2020","journal-title":"Front Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"116423","DOI":"10.1016\/j.jns.2019.116423","article-title":"Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod","volume":"405","author":"Vanoli","year":"2019","journal-title":"J Neurol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.msard.2016.09.012","article-title":"Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation","volume":"10","author":"Simula","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"B16","first-page":"274","article-title":"The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: a longitudinal study in an Iranian population","volume":"12","author":"Abdar","year":"2016","journal-title":"ARYA Atheroscler"},{"key":"B17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.msard.2015.10.009","article-title":"The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis","volume":"5","author":"Datt","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"B18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1471-2377-14-65","article-title":"Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial","volume":"14","author":"Laroni","year":"2014","journal-title":"BMC Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40120-016-0051-7","article-title":"Cardiac safety profile of first dose of fingolimod for relapsing-remitting multiple sclerosis in real-world settings: data from a german prospective multi-center observational study","volume":"5","author":"Linker","year":"2016","journal-title":"Neurol Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s12325-015-0224-2","article-title":"Safety and tolerability of fingolimod in latin american patients with relapsing-remitting multiple sclerosis: the open-label FIRST LATAM study","volume":"32","author":"Ordo\u00f1ez-Boschetti","year":"2015","journal-title":"Adv Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.msard.2013.11.001","article-title":"Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod","volume":"3","author":"Schurmann","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"B22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/ane.12573","article-title":"Early safety and efficacy of fingolimod treatment in Denmark","volume":"135","author":"Voldsgaard","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"B23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12883-016-0789-7","article-title":"Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study","volume":"17","author":"Limmroth","year":"2017","journal-title":"BMC Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.msard.2015.04.002","article-title":"Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors","volume":"4","author":"Bermel","year":"2015","journal-title":"Mult Scler Relat Disord"},{"key":"B25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2125.2008.03199.x","article-title":"The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects","volume":"66","author":"Kovarik","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1177\/1352458515604384","article-title":"Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis","volume":"22","author":"Simula","year":"2016","journal-title":"Mult Scler"},{"key":"B27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/cns.12283","article-title":"Vagomimetic effects of fingolimod: physiology and clinical implications","volume":"20","author":"Vanoli","year":"2014","journal-title":"CNS Neurosci Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s00415-017-8636-3","article-title":"Heart rate variability decreases after 3 months of sustained treatment with fingolimod","volume":"264","author":"Vehoff","year":"2017","journal-title":"J Neurol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11481-015-9619-8","article-title":"Effects of three months fingolimod therapy on heart rate","volume":"10","author":"Simula","year":"2015","journal-title":"J Neuroimmune Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/1756285616682936","article-title":"Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects","volume":"10","author":"Hilz","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e12443","DOI":"10.1111\/anec.12443","article-title":"Sequence of cardiovascular autonomic alterations after fingolimod initiation","volume":"22","author":"Simula","year":"2017","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.msard.2018.11.006","article-title":"Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?","volume":"27","author":"Kocyigit","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1212\/WNL.0000000000001049","article-title":"Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia","volume":"83","author":"Warnke","year":"2014","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1001\/jama.270.21.2590","article-title":"Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs","volume":"270","author":"Makkar","year":"1993","journal-title":"JAMA."},{"key":"B35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2165\/00002018-200124080-00002","article-title":"Is gender a risk factor for adverse drug reactions?","volume":"24","author":"Drici","year":"2001","journal-title":"Drug Saf"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1111\/jcmm.12549","article-title":"The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue","volume":"19","author":"Egom","year":"2015","journal-title":"J Cell Mol Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T04:20:36Z","timestamp":1597206036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":36,"alternative-id":["10.3389\/fneur.2020.00818"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00818","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"article-number":"818"}}